PRL and pachyonychia congenita: In a phase 2 study of pembrolizumab in rare malignancies (NCT02721732), partial responses occurred in two out of four patients who had ACTH-secreting PC [54], but not in the patient who had a non-secreting corticotroph PC, nor the one who had a prolactin-secreting PC.